CD8A and neoplasm: While our findings support the prognostic value of TIGIT+PD-1+CXCL13+ CD8+ T cells within tumor tissues, future research should also explore non-invasive biomarkers—such as immune signatures detectable in peripheral blood—that could broaden the clinical utility and accessibility of immune monitoring for CRC patients.